Latest news about Godavari Drugs
Godavari Drugs
97.00
-4.00(-3.96%)
Company Performance:
View Company Insights1D-3.96%
1M-16.42%
6M+18.54%
1Y+15.26%
5Y+45.32%
More news about Godavari Drugs
08Apr 26
Godavari Drugs Limited Submits SEBI Compliance Certificate for Q4FY26
Godavari Drugs Limited submitted its SEBI Regulation 74(5) compliance certificate for Q4FY26 to BSE Limited on April 8, 2026. The certificate, issued by registrar CIL Securities Limited, confirms proper handling of dematerialization processes during the quarter ended March 31, 2026, including verification of securities, cancellation of certificates, and timely substitution of depository names in the Register of Members.
23Mar 26
Godavari Drugs: Prashant Shrimal Files SEBI Disclosure for Share Acquisition
Godavari Drugs Limited completed significant capital raising through allotment of 23,60,065 convertible warrants and 25,96,935 equity shares on preferential basis. Promoter group member Prashant Shrimal filed SEBI disclosure confirming acquisition of 1,12,360 equity shares, representing 1.11% shareholding and 0.90% diluted shareholding, with multiple other promoters also filing regulatory disclosures for their respective warrant acquisitions.
12Feb 26
Godavari Drugs Limited Shareholders Approve Preferential Equity Share and Convertible Warrant Issuance at EGM
Godavari Drugs Limited successfully conducted its 1st EGM for FY 2025-26 on February 12, 2026, with 46 members participating via video conferencing. Shareholders overwhelmingly approved two special resolutions with 99.9998% votes in favor - one for issuing equity shares on preferential basis to promoters and non-promoters, and another for issuing convertible warrants to promoters. The meeting was chaired by Mr. Ghanshyam Jaju with full board participation, and Mrs. Vidya Harkut served as scrutinizer overseeing the electronic voting process.
11Feb 26
Godavari Drugs Reports Q3FY26 Results, Approves ₹5.50 Crore Working Capital Loan
Godavari Drugs reported Q3FY26 net profit of ₹75.76 lakhs on revenue of ₹2218.43 lakhs, showing decline from previous year's ₹76.74 lakhs profit and ₹2955.21 lakhs revenue. Nine-month performance also declined with net profit at ₹279.84 lakhs versus ₹348.69 lakhs last year. The Board approved a ₹5.50 crore short-term working capital loan from ICICI Bank with 6-month tenure for new order execution requirements.
15Jan 26
Godavari Drugs Board Approves Preferential Issue of Convertible Warrants and Equity Shares Worth ₹44.12 Crores
Godavari Drugs Limited board approved preferential issue of 23,60,065 convertible warrants and 25,96,935 equity shares at ₹89 each, raising approximately ₹44.12 crores. The warrants are exclusively for 9 promoters with 18-month conversion period, while equity shares target 31 investors including promoters and non-promoters. Post-allotment shareholding will be 51.52% promoters and 48.48% public, subject to shareholder approval in EGM scheduled February 12, 2026.
08Jan 26
Godavari Drugs Limited Issues Clarification on Share Price Movement to BSE
Godavari Drugs Limited submitted a clarification to BSE on January 8, 2026, regarding significant share price movement, confirming no unpublished price sensitive information exists. The company attributed the price volatility to market-driven demand-supply factors and reaffirmed its commitment to regulatory compliance under SEBI regulations.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Zydus Life Science
Lupin
Dr Reddys Laboratories
Mankind Pharma
Laurus Labs
Aurobindo Pharma
1,910.00
(+0.40%)
8,496.00
(-1.17%)
4,886.50
(-0.20%)
1,437.90
(+0.40%)
1,103.80
(-1.45%)
2,188.00
(-0.63%)
1,190.00
(+1.30%)
2,374.50
(-0.40%)
1,801.00
(-0.06%)
1,608.00
(-0.82%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
